Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dorin Toader

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2025
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune CellsRaghida A Bukhalid, Jeremy R Duvall, Kelly Lancaster, et al.
Journal of Medicinal Chemistry|June 2, 2018
Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase InhibitorsNeil P Grimster, Erica Anderson, Marat Alimzhanov, et al.
Molecular Cancer Therapeutics|September 29, 2023
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody RatiosSusan M Clardy, Alex Uttard, Bingfan Du, et al.
Molecular Cancer Therapeutics|May 20, 2017
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4Jay Harper, Christopher Lloyd, Nazzareno Dimasi, et al.
Molecular Cancer Therapeutics|June 9, 2023
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of CancerDorin Toader, Shawn P Fessler, Scott D Collins, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2025
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune CellsRaghida A Bukhalid, Jeremy R Duvall, Kelly Lancaster, et al.
Journal of Medicinal Chemistry|June 2, 2018
Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase InhibitorsNeil P Grimster, Erica Anderson, Marat Alimzhanov, et al.
Molecular Cancer Therapeutics|September 29, 2023
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody RatiosSusan M Clardy, Alex Uttard, Bingfan Du, et al.
Molecular Cancer Therapeutics|May 20, 2017
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4Jay Harper, Christopher Lloyd, Nazzareno Dimasi, et al.
Molecular Cancer Therapeutics|June 9, 2023
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of CancerDorin Toader, Shawn P Fessler, Scott D Collins, et al.
Pageof 3